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Coffee drinking has been associated with increased serum cholesterol levels in some, but not all, studies. A
Medline search of the English-language literature published prior to December 1998, a bibliography review, and
consultations with experts were performed to identify 14 published trials of coffee consumption. Information was
abstracted independently by two reviewers using a standardized protocol. With a random-effects model,
treatment effects were estimated by pooling results from individual trials after weighting the results by the inverse
of total variance. A dose-response relation between coffee consumption and both total cholesterol and LDL
cholesterol was identified (p < 0.01). Increases in serum lipids were greater in studies of patients with
hyperlipidemia and in trials of caffeinated or boiled coffee. Trials using filtered coffee demonstrated very little
increase in serum cholesterol. Consumption of unfiltered, but not filtered, coffee increases serum levels of total
and LDL cholesterol. Am J Epidemiol 2001;153:353–62.
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Drinking coffee is very common in Western society. In
the United States, for example, 52 percent of all persons
aged 10 years or older drink coffee (1). Demonstration of
the benefits and hazards associated with any such common
exposure is important. Some (2–8), but not all (9–11), obser-
vational studies have identified a positive association
between coffee drinking and higher levels of serum choles-
terol. This association was later found to be causal and
mediated through a cholesterol-raising effect of oils con-
tained in coffee (12, 13).
In 1965, Bellet et al. (14) reported a clinical trial of the
effect of caffeine on the level of fatty acids. Since then, a
number of investigations in humans have been published
(12, 13, 15–34). Results of these trials have been inconsis-
tent, perhaps because of small sample sizes or other design
features. Pooling the results of clinical trials provides a
means to explore the basis for heterogeneity in trial out-
comes. The objectives of this meta-analysis were to exam-
ine the effects of coffee consumption on serum lipids and to
assess whether any effect on lipids differs by type of coffee
(regular vs. decaffeinated) consumed or method of prepara-
tion (boiled vs. filtered).
MATERIALS AND METHODS
Study selection
English-language literature published prior to December
1998 was searched for all reports on the effect of coffee sup-
plementation in humans. Search strategies included 1) a
Medline search using the medical subject headings “cho-
lesterol,” “lipoprotein,” “caffeine,” and a text word “coffee”;
2) a review of reference lists from original research and
review articles; and 3) a review of the authors’ reference
files. Twenty-three papers were identified (12–34). These
articles were reviewed independently by two authors (S. J.
and J. H.) to determine whether they met a series of prede-
termined criteria for inclusion in our subsequent analyses.
Areas of disagreement or uncertainty were adjudicated by
consensus. To be included, a study had to have 1) been based
on results from human experimentation with random alloca-
tion of participants; 2) used coffee drinking as the active
treatment intervention; 3) included no intervention difference
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between the active treatment and control groups (or periods)
other than coffee consumption; and (4) provided data to cal-
culate the differences in serum total cholesterol change and
between the active and control treatments and the corre-
sponding variances of this difference.
Fourteen studies met the criteria for inclusion in our
analysis. The major reasons for exclusion were 1) nonran-
domized treatment allocation (29); 2) a lack of a concurrent
control group (29–33); 3) use of coffee oil (such as diter-
penes) as the active treatment (12, 13); and 4) insufficient
data to calculate the net change in serum lipids and their
variances from baseline to the end of follow-up (34).
Data abstraction
From each paper, the following information was
abstracted: 1) characteristics of the study population, includ-
ing sample size, age, sex, proportion with hypercholes-
terolemia, baseline coffee consumption, and serum lipid lev-
els; 2) study design, including duration of intervention, type
of treatment and control, method of coffee preparation
(boiled, filtered), coffee additives (cream, sugar, etc.), and
cups of coffee consumed per day during the trial; and 
3) change in serum lipids and the associated variance. If dif-
ferent protocols were used in the same report, they were
analyzed as separate trials, and the effects of coffee intake
were calculated as differences between the treatment groups
and the no coffee control group. In addition, separate meta-
analyses were performed for trials that compared regular
coffee use with decaffeinated coffee as well as for trials of
boiled versus filtered coffee.
Statistical analysis
For parallel trials, net change in serum lipids was calculated
as the mean difference (coffee minus control) of the change
(follow-up minus baseline) in serum lipids. For crossover tri-
als, net change was calculated as the mean difference in 
values between the end of the coffee supplementation and
control periods. For calculation of the pooled effects of the
interventions, each study was assigned a weight consisting of
the reciprocal of its total variance. Because the variances for
net changes in serum lipids were not reported directly in most
manuscripts, they were calculated from confidence intervals,
t statistics, p values, or the individual variances for interven-
tion and control groups (parallel trials) or intervention and
control periods (crossover trials). For parallel trials in which
the variance of paired differences during the trial was reported
separately for each group, we calculated a pooled variance for
net change by using standardized methods (35). When the
variance of paired differences was not reported, we calculated
it from the variance at baseline and at the end of follow-up. To
estimate covariance, correlation coefficients between the ini-
tial and final measurements of serum lipids from trials of the
same duration were used (16–18). We assumed an equal vari-
ance during the trial and in the intervention and control
groups.
Estimates of the mean effect of coffee consumption on
serum lipids and the corresponding 95 percent confidence
intervals were calculated by using both fixed-effects and 
random-effects models. These approaches yielded similar
patterns, but somewhat different effect estimates.
Homogeneity of effect size across trials was tested by Q
statistics (36). Because there was substantial and signifi-
cant variation in effect size across trials, we present the
results obtained using the random-effects model as devel-
oped by DerSimonian and Laird (36). The assumption of
heterogeneity implied by the use of the random-effects
model is plausible because durations of the trials varied
markedly, and they were conducted in samples that dif-
fered markedly by age, hypercholesterolemia status, and
other covariates. To explore the possible influence of
covariates on net change in serum lipids, we conducted a
series of prestated subgroup analyses on the basis of plau-
sibility and knowledge of the literature. Finally, univariate
and multivariate linear regression models were developed
to explore the influence of a series of covariates on net
change in serum lipids. The linear regression models were
weighted by the inverse of variance for change in serum
lipids in each trial. Variables that reached statistical signif-
icance in univariate analysis were included in the multi-
variate models. When information on mean age was miss-
ing (one trial), we used an average of the minimum and
maximum values for that trial. Information on race was
reported in only one trial. For crossover trials, we used
mean serum lipid levels during the control period as the
baseline values. Variables that reached statistical signifi-
cance in univariate analysis were included in multivariate
analysis. To examine potential publication bias, we plotted
the sample sizes of the studies against their corresponding
effect size (37) .
RESULTS
Participant and study design characteristics for the 18
comparisons of coffee drinking with no coffee drinking are
presented in table 1. The trials, which were conducted
between 1985 and 1992, varied in sample size from 12 to
120 participants, with a median of 47 participants per trial.
The total number of participants was 885, but 147 (16.6 per-
cent) and 34 (3.8 percent) of them were evaluated twice and
three times, respectively, receiving different treatments in
separate protocols. All of the trials were conducted on
adults, with a range of mean ages of 26–49 years. Nine of
the 18 trials included both men and women, while men were
the sole participants in the remaining nine trials. Five trials
(135 participants) were conducted with hyperlipidemic
patients. Persons on lipid-lowering drug therapy were
excluded from one study (17). A crossover design was used
in six trials, while parallel arm design was used in the
remaining 12. All of the trials were single-blind. Average
pretreatment total cholesterol ranged from 190.8 to 335.9
mg/dl (median, 213.5 mg/dl).
Characteristics of the intervention in the 18 trials of cof-
fee drinking versus no coffee drinking are given in table 2.
The trials varied in length from 21 to 79 days, with a
median duration of 56 days. The control group received no
coffee in 16 trials. In the remaining two trials (18, 19), the
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control group received tea. Regular coffee was used as the
active treatment in 15 of the 18 trials, and decaffeinated
coffee was used in the other three trials. In five of the 18 tri-
als, coffee was boiled, and in 10, it was filtered. In three tri-
als, it was not specified whether coffee was boiled or fil-
tered, and in one trial, instant coffee was given. The dose of
coffee consumption in the active treatment group varied
from three to eight cups per day, with a median of six cups
per day. Methods of controlling for dietary changes during
the trial, weight assessment, and coffee brewing are also
given. Information on coffee additives was not available for
most studies (18, 21, 25, 30, 31). For studies in which such
information was given, several strategies were used.
Adjustment was performed for change in the amount of
creamer used (23); addition of cream, nondairy additives,
or sugar was not permitted (24); aspartame, skim milk, and
TABLE 1. Participant and study design characteristics of 18 trials of coffee drinking versus no coffee consumption in English-
language literature published prior to December 1998
Forde, 1985a (15)
Forde, 1985b (15)
Forde, 1985c (15)
Aro, 1985 (16)
Aro, 1987a (17)
Aro, 1987b (17)
Bak, 1989a (18)
Bak, 1989b (18)
Burr, 1989a (19)
Burr, 1989b (19)
Rosmarin, 1990 (20)
Superko, 1991a (21)
Superko, 1991b (21)
Van Dusseldorp, 1991a (22)
Van Dusseldorp, 1991b (22)
Fried, 1992a (23)
Fried, 1992b (23)
Fried, 1992c (23)
Author and year
(reference no.)
Sample
size*
Age (years) Baseline lipids (mg/dl)
%
male Masking HDL
cholesterol†
8/9
8/9
8/9
12
42
42
33/34
34/34
54
54
11/10
62/58
61/58
22/21
21/21
25/25
25/25
25/25
45
45
45
49
49
49
26
26
35
35
36
46
46
39
39
44
44
44
35–54
35–54
35–54
35–45
31–60
31–60
18–58
18–58
22–45
17–57
17–57
20–60
20–60
20–60
Mean Range
%
hyperlip-
idemic
Study
design
Habitual
coffee
intake
(cups/
day)
TC† LDL
cholesterol† TG†
100
100
100
50
50
50
54
53
65
65
100
100
100
51
52
100
100
100
100
100
100
0
100
100
0
0
0
0
0
0
0
0
0
0
0
0
P†
P
P
X†
X
X
P
P
X
X
X
P
P
P
P
P
P
P
NA†
NA
NA
NA
NA
NA
Single
Single
Single
Single
NA
Double
Double
NA
NA
Open
Open
Open
7.3
7.3
7.3
4.5
6.5
6.5
5.6
5.6
3.5
3.5
3.9
4.5
4.5
5.5
5.5
4.5
4.5
4.5
335.9
335.9
335.9
193.7
306.3
310.1
199.3
195.7
190.8
211.5
213.5
206.9
204.9
201.1
201.6
201.1
32.7
58.4
58.0
48.9
48.0
37.7
50.8
50.1
59.9
56.1
53.0
53.9
52.4
116.8
227.0
235.9
126.8
121.0
124.9
141.3
143.5
129.5
129.5
127.8
129.0
128.8
30.2
70.4
61.5
108.8
44.1
59.0
40.6
44.5
47.0
39.6
42.7
* Active treatment group/control group.
† TC, total cholesterol; HDL cholesterol, high density lipoprotein cholesterol; LDL cholesterol, low density lipoprotein cholesterol; TG, triglyceride; P, parallel
arm; NA, not available; X, crossover.
TABLE 2. Intervention characteristics of 18 trials of coffee drinking versus no coffee consumption in English-language literature
published prior to December 1998
Forde, 1985a (15)
Forde, 1985b (15)
Forde, 1985c (15)
Aro, 1985 (16)
Aro, 1987a (17)
Aro, 1987b (17)
Bak, 1989a (18)
Bak, 1989b (18)
Burr, 1989a (19)
Burr, 1989b (19)
Rosmarin, 1990 (20)
Superko, 1991a (21)
Superko, 1991b (21)
Van Dusseldorp, 1991a (22)
Van Dusseldorp, 1991b (22)
Fried, 1992a (23)
Fried, 1992b (23)
Fried, 1992c (23)
Author and year
(reference no.)
Duration
(days)
Cups/
day
70
70
70
21
28
28
63
63
28
28
28
56
56
79
79
56
56
56
Regular
Regular
Habitual
Instant
Regular
Regular
Regular
Regular
Decaffeinated
Regular
Regular
Regular
Decaffeinated
Regular
Regular
Regular
Regular
Decaffeinated
7.3
7.3
7.3
8.0
8.0
8.0
6.0
6.0
5.0
5.0
3.6
4.0
4.0
6.0
6.0
3.0
5.0
5.0
Type
of
coffee
Control for
diet change
BMI*/
weight Brewing method
Advice†
Advice
Advice
Advice
Advice
Advice
Fat record
Fat record
Fat record
Fat record
Monthly diet log
4-day record
4-day record
1-day recall
1-day recall
3-day recall
3-day recall
3-day recall
NA*
NA
NA
Weight
Weight
Weight
Weight
Weight
Weight
Weight
Weight
Weight
Weight
Weight
Weight
BMI
BMI
BMI
50 g ground coffee, 1 liter of boiling water, sit for 10 minutes
50 g ground coffee, filtered (Moccamaster, Technivorm type 70)‡
“Habitual”
2 g lyophilized instant coffee, hot water
56 g coffee (8 standard spoonfuls of 7 g each), boiled
56 g coffee (8 standard spoonfuls of 7 g each), filtered
20 g ground coffee in 0.5 liters of boiling water, sit for 10 minutes
Drip, filtered
NA
NA
Filtered
Drip, standard amounts of ground coffee, filtered
Drip, standard amounts of ground coffee, filtered
0.5 liter boiling water poured onto 25 g coarse grounds; unfiltered
0.5 liter boiling water poured onto 25 g coarse grounds; filtered
1,260 ml water, 8 level scoops of coffee, 72 g of caffeinated 
coffee, filtered
1,260 ml water, 8 level scoops of coffee, 72 g of caffeinated 
coffee, filtered
1,260 ml water, 8 level scoops of coffee, 64 g of decaffeinated
coffee, filtered
* BMI, body mass index; NA, not available.
† Advice, advised not to change their diet.
‡ Technivorm, Ameongen, the Netherlands.
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FIGURE 1. Net change and 95% confidence intervals in total cholesterol associated with coffee drinking in 18 clinical trials published in
English-language literature prior to December 1998. The overall effect is weighted by the inverse of the total variance of each trial.
nonfat powered dry milk, but no other additives, were per-
mitted (26); and, in a crossover trial, if milk and sugar were
used during the coffee period, they were also used during
the tea period (17, 20).
Total cholesterol increased in the active treatment group
compared with the corresponding control group in 16 (89
percent) of the 18 trials; in nine trials (50 percent), the lower
bound of the 95 percent confidence interval was greater than
zero (figure 1). Overall, coffee drinking increased total cho-
lesterol by 11.8 mg/dl (p < 0.001).
Low density lipoprotein cholesterol (LDL cholesterol)
increased in the active treatment group compared with the
corresponding control group in 11 (73 percent) of the 15 tri-
als in which it was measured; in four (27 percent) trials, the
lower bound of the 95 percent confidence interval was
greater than zero (figure 2). The pooled estimate of the
effect of coffee drinking on LDL cholesterol was an increase
of 6.5 mg/dl (p  0.01, 95 percent CI: 2.0, 11.0).
The overall pooled estimates of the effect of coffee
drinking were 0.2 mg/dl for high density lipoprotein
cholesterol (HDL cholesterol) (p  0.75), 5.9 mg/dl for
triglyceride (p  0.02), 1.2 mg/dl for apolipoprotein A
(p  0.37), and 3.9 mg/dl for apolipoprotein B (p 
0.01).
There was considerable variation across the 18 trials in
the estimate of intervention-related average net change in
serum lipids and in the width of the associated 95 percent
confidence intervals. Compared with controls, coffee con-
sumption was associated with an average net change in
serum lipids that ranged from –0.4 to 58.4 mg/dl for total
cholesterol, –3.9 to 5.0 mg/dl for HDL cholesterol, –8.1 to
45.2 mg/dl for LDL cholesterol, and –2.3 to 14.3 mg/dl for
triglyceride. Based on a test of homogeneity, the variation in
estimated effect size was significant (p < 0.0001) for total
cholesterol, HDL cholesterol, LDL cholesterol, triglyceride,
apolipoprotein A, and apolipoprotein B. The plot of sample
size versus effect size was “funnel” shaped with little varia-
tion in the effect size for the studies with a larger sample
size and an increasing spread of effect size in the studies
with a smaller sample size (figure 3). Accordingly, the dis-
tribution of effect sizes seen in individual studies was sym-
metrically distributed around the pooled mean effect size.
Table 3 summarizes the pooled estimates of treatment
effect in subgroups of trials defined according to partici-
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FIGURE 2. Net change and 95% confidence intervals in low density lipoprotein cholesterol (LDL cholesterol) associated with coffee drinking
in 15 clinical trials published in English-language literature prior to December 1998. The overall effect is weighted by the inverse of the total vari-
ance of each trial.
FIGURE 3. Plot of effect on total cholesterol (mg/dl) by sample size in 18 clinical trials of coffee drinking published prior to December 1998.
pant characteristics and study design features. As also
noted in figure 1, the results were more marked in trials of
persons with hypercholesterolemia; cholesterol increased
by 33.5 mg/dl (95 percent CI: 16.7, 50.4) in the coffee-
drinking groups compared with controls in such patients.
In trials that excluded persons with hypercholesterolemia,
the average change in cholesterol was 6.1 mg/dl (95 per-
cent CI: 2.1, 10.1). However, the most notable finding in
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FIGURE 4. Net change in total cholesterol by amount of coffee supplementation in 18 trials published before December 1998. Diameter of cir-
cles is proportional to the inverse of the total variance of each trial.
TABLE 3. Net change in total and LDL cholesterol† by study characteristics of 18 trials of coffee versus no coffee consumption
in English-language literature published prior to December 1998
Overall
Sample size
<43
≥43
Age(years)
<50
≥50
Hyperlipidemic participants
No
Yes
Design
Parallel
Crossover
Duration of intervention
(weeks)
<8
≥8
Type of coffee
Regular
Decaffeinated
Filtered
Yes
No
Amount of coffee (cups)
<6
≥6
Variables
No.
Total cholesterol (mg/dl) LDL cholesterol (mg/dl)
18
9
9
8
10
13
5
12
6
6
12
15
3
10
8
8
10
11.8 (6.8, 16.0)
21.8 (10.7, 32.6)
8.6 (1.7, 10.6)
8.2 (1.5, 14.8)
15.2 (8.3, 22.1)
6.1 (2.1, 10.1)
33.5 (16.7, 50.4)
11.7 (6.1, 17.2)
12.5 (–0.6, 25.6)
12.5 (–0.6, 25.6)
11.7 (6.1, 17.2)
14.2 (7.8, 20.7)
3.6 (–1.9, 9.0)
3.2 (0.6, 5.8)
23.0 (11.9, 34.9)
2.0 (–0.4, 4.4)
21.6 (12.5, 30.7
Net change
(95% CI†)
p
value*
p
value**
<0.001
<0.001
0.011
0.008
<0.001
<0.0001
0.025
<0.001
0.031
0.031
<0.001
<0.001
0.100
0.01
<0.001
0.0548
<0.001
0.052
0.17
0.01
0.99
0.99
0.02
0.004
<0.001
15
6
9
8
7
13
2
9
6
6
9
12
3
9
3
8
7
6.5 (2.0, 11.0)
1.6 (–5.6, 8.7)
7.1 (2.2, 12.1)
4.9 (–1.8, 11.6)
8.2 (1.6, 14.8)
4.3 (0.3, 8.3)
27.9 (–2.1, 57.9)
4.8 (–0.4, 9.9)
10.3 (0.1, 20.6)
10.3 (0.1, 20.6)
4.8 (–0.4, 9.9)
7.0 (0.9, 13.1)
5.5 (1.6, 9.4)
2.6 (–0.8, 6.0)
13.6 (3.4, 23.9)
3.2 (0.5, 6.0)
11.9 (1.7, 22.1)
0.002
0.336
0.003
0.075
0.007
0.019
0.033
0.035
0.024
0.024
0.035
0.012
0.004
0.067
0.005
0.011
0.011
0.24
0.50
0.15
0.36
0.36
0.69
0.07
0.13
* Within strata p value.
** Test of homogeneity between strata.
† LDL cholesterol, low density lipoprotein cholesterol; CI, confidence interval.
No. Net change(95% CI)
p
value*
p
value**
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subgroup analyses was greater intervention-related
increases compared with controls in total cholesterol (p <
0.001) and LDL cholesterol (p  0.03) in the trials that
used nonfiltered coffee as the active treatment compared
with those that used filtered coffee. There was also a
greater effect on total cholesterol in trials that used regu-
lar coffee as the active intervention compared with the few
trials with decaffeinated coffee as the active treatment.
Total cholesterol increased to a larger extent in trials in
which six cups or more of coffee were consumed com-
pared with those in which the participants drank fewer
than six cups of coffee per day. Figure 4 displays the net
change in total cholesterol by cups of coffee consumed. A
dose-response relation was seen with trials that adminis-
tered higher doses of coffee, demonstrating larger
increases in serum cholesterol.
Tables 4 and 5 display participant, study design, and
intervention characteristics of the 14 trials that tested intake
of boiled versus filtered coffee or regular versus decaf-
feinated coffee drinking. Some of the treatment arms are the
same as those listed in table 1, but the comparison groups
differ (15, 17–19, 21, 23). These trials, which were con-
ducted between 1985 and 1995, varied in sample size from
17 to 113 participants, with a median of 50 persons per trial.
Table 6 displays pooled results from these trials. In the eight
trials of regular versus decaffeinated coffee, there was no
difference in the effect of the two treatments on serum lipid
values. In contrast, pooled results of six trials that compared
the effects of boiled with filtered coffee showed signifi-
cantly greater increases in serum lipoprotein levels in the
participants who drank boiled coffee than in those who
drank filtered coffee.
In multiple linear regression analysis, the number of cups
of coffee administered was independently associated with
change in total cholesterol and LDL cholesterol (table 7).
Older age was independently associated with a greater net
change in LDL cholesterol. Substantially greater effects of
coffee consumption on both total cholesterol and LDL cho-
lesterol were reported in trials in which the participants
drank boiled coffee. Approximately 88.1 percent of the vari-
ance in total cholesterol and 86.2 percent of the variance in
LDL cholesterol-related treatment effect size could be
explained by the five variables included in the multivariate
model.
DISCUSSION
To the best of our knowledge, this is the first quantita-
tive review of randomized clinical trials yielding informa-
tion on the effect of coffee consumption on serum lipids. It
demonstrates that, on average, drinking six cups of coffee
was significantly associated with an increase in total cho-
lesterol (11.8 mg/dl), LDL cholesterol (6.5 mg/dl), and
triglyceride (5.9 mg/dl), but not HDL cholesterol (0.2
mg/dl) levels. The relation between coffee intake and
serum lipids persisted after controlling for the mean age of
the study participants and the method of coffee prepara-
tion. The effect of coffee drinking on total cholesterol was
mediated almost solely through its effect on LDL choles-
terol and was more pronounced in trials in which the par-
ticipants drank boiled coffee, had hyperlipidemia, drank
more coffee, and were, on average, older. Pooled results of
the trials that used filtered coffee demonstrated only mini-
mal effects of coffee on serum cholesterol levels. These
results are reassuring for the vast majority of Americans
who drink filtered coffee.
Heavy consumption of caffeine or coffee has long been
suspected to have a cholesterol-raising effect, but cross-sec-
tional studies investigating the associations have yielded
conflicting results (2–4, 38–45). These inconsistencies may
reflect variation in the choice of the comparison group (no
coffee vs. decaffeinated coffee), variation in methods of cof-
TABLE 4. Participant and study design characteristics of 14 trials comparing boiled with filtered coffee (n = 6) or caffeinated
with decaffeinated coffee (n = 8) in English-language literature published prior to December 1998
Forde, 1985 (15)
Aro, 1987 (17)
Burr, 1989 (19)
Bak, 1989 (18)
Aro, 1990 (24)
van Dusseldorp, 1990 (25)
Superko, 1991 (21)
van Dusseldorp, 1991 (22)
Ahola, 1991 (26)
Fried, 1992a (23)
Fried, 1992b (23)
Wahrburg 1994a (27)
Wahrburg, 1994b (27)
Sanguigni, 1995 (28)
Author and year
(reference no.)
Sample
size*
Age (years) Baseline cholesterol (mg/dl)
%
male Masking HDL
cholesterol†
8/8
42
54
33/34
20/21
45
52/61
21/22
11/9
25/25
25/25
39/39
39/38
49
45
49
35
26
45
38
46
39
45
44
44
25
25
23
35–54
35–45
18–58
23–61
25–45
17–57
20–60
20–60
21–28
Mean Range
%
hyper-
lipidemic
Study
design*
Baseline
coffee
intake
(cups/
day)
TC† LDL
cholesterol† TG†
100
50
65
54
46
49
100
51
85
100
100
51
51
51
100.0
0
0
0
0
0
0
0
0
0
0
0
0
0
P†
X†
X
P
X
X
P
P
X
P
P
P
P
X
NA†
NA
Single
Single
NA
Double
Double
NA
NA
Open
Open
NA
NA
Double
7.3
4.5
3.5
5.6
5.7
4–6
4.5
5.5
7.0
4.5
4.5
3–6
3–6
>5.0
310.1
194.5
215.0
215.8
204.9
216.6
204.6
204.6
209.5
209.5
173.6
57.0
45.6
58.8
49.9
54.1
146.9
54.5
54.5
60.3
60.3
38.7
235.9
118.3
145.0
131.5
146.9
127.6
127.6
131.1
131.1
104.4
61.5
46.4
34.8
39.8
39.8
* Active treatment group/control group.
† TC, total cholesterol; HDL cholesterol, high density lipoprotein cholesterol; LDL cholesterol, low density lipoprotein cholesterol; TG, triglyceride; P, parallel
arm; NA, not available; X, crossover.
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fee preparation between the studies, or confounding. One
prospective study has found a lipid-raising effect for habit-
ual coffee consumption (7). In that investigation, drinking
one cup of regular coffee a day was associated with about a
2-mg/dl increase in total cholesterol over 16.7 months of
follow-up after adjustment for age and changes in other
potential confounders. This result is similar to the effect
observed in this quantitative summary of clinical trials (11.8
mg/dl higher serum cholesterol with ingestion of six cups
per day). In observational studies, the association between
coffee consumption and higher serum cholesterol levels
might be due to an effect of coffee additives, such as milk
and cream, rather than to coffee consumption per se. This is
not the case in the clinical trials used in our meta-analysis,
however, because use of additives was controlled in almost
all trials.
In this summary, trials using a control group that con-
sumed decaffeinated coffee identified no effect of drinking
regular coffee on serum cholesterol. This suggests that the
cholesterol-raising effect of coffee is not due to the caffeine
itself but to another ingredient of coffee (46, 47). The lipid-
raising effects of coffee drinking have been reported to be
primarily due to coffee oils, such as cafestol and kahweol
(12, 13), that increase the synthesis of cholesterol by
decreasing excretion of bile acids and neutral sterols (48).
Boiled coffee has a higher concentration of coffee oils
because of the higher temperatures used during its prepara-
tion (17) and the longer contact time between the coffee
grounds and water (17, 38). Filtration of coffee through a
paper filter removes the cholesterol-raising fraction from the
coffee extract (22, 32). Consistent with these observations,
trials using boiled or nonfiltered coffee had a stronger cho-
lesterol-raising effect than did those using filtered coffee
(table 3).
Several lines of evidence favor the presence of a causal
relation between coffee drinking and higher levels of total
cholesterol and LDL cholesterol serum lipids. The 95 per-
cent confidence intervals around the estimate of effect size
make it unlikely that the associations noted reflect a
chance finding. Another finding favoring causality is the
presence of a dose-response relation between coffee and
serum lipids. Similarly important is replication of the rela-
tion in studies conducted in different populations and with
different study designs. Finally, the association is biologi-
cally plausible.
A limitation of our approach is that only articles pub-
lished in the English language were included. Limited
resources prevented us from including articles published in
other languages. Studies in the English-language literature
may show a greater intervention effect than does research
that is never published or is published in languages other
than English. From analysis of the funnel plot, however,
there was no evidence that publication bias contributed to
the observed results.
In summary, our findings provide support for a causal
relation between intake of unfiltered coffee and a higher
cholesterol level. The average effect size noted in the 
trials comparing unfiltered with filtered coffee was rela-
tively large and may have therapeutic importance. TheseTA
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results confirm that coffee should be filtered prior to
drinking.
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